Related Experiment Video

Updated: Apr 28, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.1K

RIFAMPICIN: an antibiotic with brain protective function

Burak Yulug1, Lütfü Hanoglu1, Ertugrul Kilic2

  • 1Department of Neurology, University of Istanbul-Medipol, Istanbul, Turkey.

Brain Research Bulletin
|June 7, 2014
PubMed

Insights

Rifampicin, known for antibiotic properties, also protects the brain in conditions like stroke and neurodegenerative diseases. This review updates its unique therapeutic potential in various brain disorders.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Rifampicin is primarily recognized for its antibiotic properties.
  • Emerging evidence suggests significant neuroprotective roles for rifampicin.
  • These roles extend to both acute and chronic neurological conditions.

Purpose of the Study:

  • To provide an updated review of rifampicin's unique brain protective functions.
  • To explore its therapeutic potential in diverse neurological diseases.
  • To consolidate current knowledge on rifampicin's neuroactivity.

Main Methods:

  • Literature review of existing studies on rifampicin and neurological conditions.
  • Analysis of research data on rifampicin's mechanisms in brain protection.
  • Synthesis of findings related to its efficacy in various disease models.

Main Results:

  • Rifampicin demonstrates neuroprotective effects in acute cerebral ischemia (stroke).
  • It exhibits beneficial functions in chronic neurodegenerative conditions.
  • Specific diseases highlighted include Parkinson's disease, meningitis, Alzheimer's disease, and optic nerve injury.

Conclusions:

  • Rifampicin possesses multifaceted brain protective capabilities beyond its antibiotic action.
  • Its unique activity warrants further investigation for treating a spectrum of neurological disorders.
  • Rifampicin represents a promising therapeutic agent for neurological diseases.
Keywords:
Alzheimer's diseaseMeningitisOptic nerve injuryParkinson's diseaseRifampicinStroke

More Related Videos

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry10:58

Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry

Published on: September 27, 2020

4.6K
Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats09:43

Using Optogenetics to Reverse Neuroplasticity and Inhibit Cocaine Seeking in Rats

Published on: October 5, 2021

2.6K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
47.3K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.8K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
102